T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease
Adedigbo A. Fasanmade(TetraLogic Pharmaceuticals (United States)), Marion Blank(Janssen (United States)), Omoniyi J. Adedokun(Western University), Honghui Zhou(Janssen (United States)), Hugh M. Davis(South College), Jewel Johanns(Johnson & Johnson (United States))
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k